YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies

This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with advanced hepatobiliary and pancreatic malignancies.

Trial Details

NCT ID
NCT07763301
Phase
PHASE1
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • YMN-136 vaccine
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Voluntarily sign the informed consent form, and be able to understand and agree to comply with the study procedures and visits as specified in the …
  • Age: 18 to 75 years old, male or female.
  • Patients with pathologically or histologically confirmed, unresectable advanced hepatobiliary and pancreatic malignancies who must have experienced…
  • (1) Patients with advanced hepatocellular carcinoma who have failed standard therapy, defined as disease progression after prior treatment with PD-…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →